Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 1, 2009, Pages 6-10

  Ohori, Makoto ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; Prostate cancer; Prostate specific antigen

Indexed keywords

BIOLOGICAL MARKER; DNA;

ARTICLE; BIOTECHNOLOGY; CANCER DIAGNOSIS; CANCER STAGING; DISEASE COURSE; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; JAPAN; NOMOGRAM; OUTPATIENT DEPARTMENT; PREDICTION; PROGNOSIS; PROSTATE CANCER; PROTEOMICS; PSAMMOMA BODY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TISSUE MICROARRAY;

EID: 79959847633     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Wang MC, Valenzuela LA, Murphy GP, et al: Purification of a human prostate specific antigen. Invest Urol 17: 159-163, 1979. (Pubitemid 10132507)
2. Catalona WJ, Partin AW, Slawin KM, et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279: 1542-1547, 1998. (Pubitemid 28233009)
3. Partin AW, Brawer MK, Bartsch G, et al: Complexed prostate specific antigen improves specificity for prostate cancerdetection: results of a prospective multicenter clinical trial. J Urol 170: 1787-1791, 2003. (Pubitemid 37254929)
4. Mikolajczyk SD, Grauer LS, Miller LS, et al: A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50: 710-714, 1997. (Pubitemid 27494991)
5. Mikolajczyk SD, Marker KM, Miller LS, et al: A truncated precursor form of prostate-specific antigen is a more specific marker of prostate cancer. Cancer Res 61: 6958-6963, 2001. (Pubitemid 32896525)
6. Catalona WJ, Bartsh G, Rittenhouse HG, et al: Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170: 2181-2185, 2003. (Pubitemid 37413952)
7. Benson MC, McMahon DJ, Cooner WH, et al: An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density. World Urol 11: 206-213, 1993.
8. Kikuchi E, Nakashima J, Ishibashi M, et al: Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma. Cancer 89: 842-849, 2000. (Pubitemid 30658584)
9. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.
10. Pollack A, DrSilvio M, Khor LY, et al: Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 22: 2133-2140, 2004. (Pubitemid 41095146)
11. Bubendorf L, Tapia C, Gasser TC, et al: Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 29: 949-954, 1998. (Pubitemid 28422042)
12. Pagno M, Tam SW, Theodoras AM, et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cycline-dependent kinase inhibitor p27. Science 269: 682-685, 1995.
13. Cordon-Cardo C, Koff A, Drobnjak M, et al: Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90: 1284-1291, 1998. (Pubitemid 28433473)
14. Freedland SJ, deGregorio F, Sacoolidge JC, et al: Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol 169: 1325-1330, 2003. (Pubitemid 36323777)
15. Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, and prostate cancer. Science 275: 1943-1947, 1997.
16. Cairns P, Okami K, Halachmi S, et al: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57: 4997-5000, 1997. (Pubitemid 27498107)
17. Neshat MS, Mellinghoff IK, Tran C, et al: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/ mTOR. Proc Natl Acad Sci USA 98: 10314-10319, 2001. (Pubitemid 32803017)
18. Cavallaro U and Christofori G: Cell adhesion and signalling by Cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4: 118-132, 2004. (Pubitemid 38198740)
19. Umbas R, Isaacs WB, Bringuier PP, et al: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate caner. Cancer Res 54: 3929-3933, 1994. (Pubitemid 24241218)
20. Luo J, Zha S, Gage WR, et al: Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62: 2220-2226, 2002. (Pubitemid 34411693)
21. Rubin MA, Zhou M, Dhanasekaran SM, et al: alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287: 1662-1670, 2002. (Pubitemid 34289218)
22. Yang XJ, Laven B, Tretiakova M, et al: Detection of alpha-methylacyl- coenzyme A racemase in postradiation prostatic adenocarcinoma. Urology 62: 282-286, 2003. (Pubitemid 36952078)
23. Massague J, Blain SW, Lo RS, et al: TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309, 2000.
24. Shariat SF, Shalev M, Menesses-Diaz A, et al: Preoperative plasma levels of tyranforming growth factor beta (1) (TGF-beta (1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 19: 2856-2864, 2001. (Pubitemid 32538195)
25. Debes JD, Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351: 1488-1490, 2004.
26. Li R, Wheeler T, Dai H, et al: High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy. Am J Surg Pathol 28: 928-934, 2004. (Pubitemid 38856850)
27. Neumann AA and Reddel RR: Tolemere maintenance and cancer-look, no telomerase. Nat Rev Cancer 2: 879-884, 2002.
28. Sommerfeld HJ, Meeker AK, Piatyszek MA, et al: Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 56: 218-222, 1996. (Pubitemid 26011466)
29. Hockenbery D, Nunez G, Milliman C, et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990. (Pubitemid 120029101)
30. Scherr DS, Vaughan ED, Jr, Wei J, et al: BCL-2 and p53 expression in clinically localized prostate cancer predict response to external beam radiotherapy. J Urol 162: 12-16, 1999.
31. Stackhouse GB, Sesterhenn IA, Bauer JJ, et al: p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 162: 2040-2045, 1999.
32. Zeng Y, Opeskin K, Baldwin ME, et al: Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 10: 5137-5144, 2004. (Pubitemid 39099788)
33. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991.
34. Borre M, Stausbol-Gron B and Overgaard J: p53 accumulation associated with bcl-2, the prolification marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 21: 171-176, 2003.
35. Fraig TW, Nordeen SK, Scott Lucia M, et al: Conference report and review: Current status of biomarker potentially associated with prostate cancer outcomes. J Urol 177: 1229-1237, 2007. (Pubitemid 46435961)